ProVise Management Group LLC Has $14.03 Million Stake in Becton, Dickinson and Company (NYSE:BDX)

Key Points

• ProVise Management Group LLC increased its stake in Becton, Dickinson and Company by 31.9% in the first quarter, now holding 61,269 shares valued at $14.03 million.
• More than 86% of Becton, Dickinson's stock is owned by institutional investors, with T. Rowe Price Investment Management increasing its holdings by 36.1% in the latest quarter.
• Becton, Dickinson and Company reported quarterly earnings of $3.35 per share, exceeding analysts' expectations, although its revenue fell short at $5.27 billion.

ProVise Management Group LLC raised its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 31.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 61,269 shares of the medical instruments supplier's stock after acquiring an additional 14,808 shares during the period. Becton, Dickinson and Company makes up 1.2% of ProVise Management Group LLC's portfolio, making the stock its 25th biggest holding. ProVise Management Group LLC's holdings in Becton, Dickinson and Company were worth $14,034,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in BDX. T. Rowe Price Investment Management Inc. grew its holdings in Becton, Dickinson and Company by 36.1% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 12,126,707 shares of the medical instruments supplier's stock valued at $2,751,187,000 after buying an additional 3,219,317 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Becton, Dickinson and Company by 10.8% in the first quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier's stock valued at $1,567,654,000 after acquiring an additional 667,957 shares during the period. Invesco Ltd. grew its stake in shares of Becton, Dickinson and Company by 6.7% in the fourth quarter. Invesco Ltd. now owns 4,265,638 shares of the medical instruments supplier's stock worth $967,745,000 after acquiring an additional 267,436 shares during the last quarter. Kovitz Investment Group Partners LLC increased its position in Becton, Dickinson and Company by 392.4% during the fourth quarter. Kovitz Investment Group Partners LLC now owns 3,416,665 shares of the medical instruments supplier's stock worth $775,139,000 after acquiring an additional 2,722,829 shares during the period. Finally, Northern Trust Corp raised its stake in Becton, Dickinson and Company by 4.4% during the 4th quarter. Northern Trust Corp now owns 2,724,354 shares of the medical instruments supplier's stock valued at $618,074,000 after purchasing an additional 115,943 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Trading Down 1.7%

BDX stock opened at $178.39 on Friday. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99. The company has a current ratio of 1.13, a quick ratio of 0.64 and a debt-to-equity ratio of 0.70. The business's 50 day moving average is $174.83 and its 200-day moving average is $201.28. The firm has a market cap of $51.13 billion, a P/E ratio of 34.04, a P/E/G ratio of 1.37 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, beating analysts' consensus estimates of $3.28 by $0.07. The firm had revenue of $5.27 billion for the quarter, compared to analysts' expectations of $5.35 billion. Becton, Dickinson and Company had a return on equity of 15.99% and a net margin of 7.28%. The business's revenue was up 4.5% compared to the same quarter last year. During the same period in the prior year, the business posted $3.17 earnings per share. Equities analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be given a dividend of $1.04 per share. The ex-dividend date is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.3%. Becton, Dickinson and Company's dividend payout ratio (DPR) is 79.39%.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP David Shan sold 1,166 shares of the business's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $171.19, for a total value of $199,607.54. Following the transaction, the executive vice president directly owned 4,575 shares in the company, valued at $783,194.25. The trade was a 20.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Michael David Garrison sold 1,185 shares of the company's stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the sale, the executive vice president directly owned 4,887 shares in the company, valued at $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.36% of the company's stock.

Analyst Ratings Changes

BDX has been the topic of several research analyst reports. Bank of America lowered shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 price target on the stock. in a research report on Thursday, May 1st. Morgan Stanley decreased their target price on Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 6th. The Goldman Sachs Group cut Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price target for the company. in a report on Friday, May 2nd. Wall Street Zen downgraded Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a research report on Friday, May 2nd. Finally, Citigroup cut Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and lowered their price objective for the company from $217.00 to $185.00 in a research report on Thursday, May 22nd. Eight research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $219.22.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.